Additionally, the 36-month beta value for VSTM is 0.85. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for VSTM is 48.47M and currently, short sellers hold a 27.40% ratio of that float. The average trading volume of VSTM on June 02, 2025 was 1.42M shares.
VSTM) stock’s latest price update
Verastem Inc (NASDAQ: VSTM)’s stock price has dropped by -19.02 in relation to previous closing price of 7.52. Nevertheless, the company has seen a loss of -26.71% in its stock price over the last five trading days. businesswire.com reported 2025-06-02 that BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known as VS-7375 in the U.S.). As of May 16, 2025, 23 efficacy-evaluable patients with pancreatic ductal adenocarcinoma (PDAC) and 12 efficacy-evaluable patients with non-small cell lung cancer (NSCLC) achieved an overall.
VSTM’s Market Performance
Verastem Inc (VSTM) has experienced a -26.71% fall in stock performance for the past week, with a -18.03% drop in the past month, and a 9.93% rise in the past quarter. The volatility ratio for the week is 6.43%, and the volatility levels for the past 30 days are at 5.54% for VSTM. The simple moving average for the past 20 days is -17.94% for VSTM’s stock, with a 22.91% simple moving average for the past 200 days.
Analysts’ Opinion of VSTM
Many brokerage firms have already submitted their reports for VSTM stocks, with Jefferies repeating the rating for VSTM by listing it as a “Buy.” The predicted price for VSTM in the upcoming period, according to Jefferies is $15 based on the research report published on April 10, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see VSTM reach a price target of $10, previously predicting the price at $7. The rating they have provided for VSTM stocks is “Buy” according to the report published on March 24th, 2025.
BTIG Research gave a rating of “Buy” to VSTM, setting the target price at $20 in the report published on December 31st of the previous year.
VSTM Trading at -8.44% from the 50-Day Moving Average
After a stumble in the market that brought VSTM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.08% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VSTM starting from Calkins Daniel, who sale 11,143 shares at the price of $8.13 back on May 20 ’25. After this action, Calkins Daniel now owns 114,055 shares of Verastem Inc, valued at $90,593 using the latest closing price.
Paterson Dan, the President and CEO of Verastem Inc, sale 58,677 shares at $8.13 during a trade that took place back on May 20 ’25, which means that Paterson Dan is holding 461,982 shares at $477,044 based on the most recent closing price.
Stock Fundamentals for VSTM
Current profitability levels for the company are sitting at:
- -5461.29 for the present operating margin
- 0.25 for the gross margin
The net margin for Verastem Inc stands at -6203.21. The total capital return value is set at -1.36. Equity return is now at value -2159.50, with -116.66 for asset returns.
Based on Verastem Inc (VSTM), the company’s capital structure generated 1.8 points at debt to capital in total, while cash flow to debt ratio is standing at -1.58. The debt to equity ratio resting at -2.24. The interest coverage ratio of the stock is -40.45.
Currently, EBITDA for the company is -125.86 million with net debt to EBITDA at 0.33. When we switch over and look at the enterprise to sales, we see a ratio of 12145.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.50.
Conclusion
In conclusion, Verastem Inc (VSTM) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
